NEWGENIVF tumbles 33% after reverse split amid $45M UAE real estate push

Company Overview

NEWGENIVF GROUP LIMITED, trading on the Nasdaq Capital Market under the ticker NIVF, is a British Virgin Islands holding company that provides fertility services across Asia. Through subsidiaries in Thailand, Cambodia, and Kyrgyzstan, the company offers in vitro fertilization and related treatments to its patient base.

Corporate Structure and Operations

NEWGENIVF operates as a holding company with primary clinical and business functions managed by its subsidiaries. The executive team, led by CEO Siu Wing Fung Alfred, oversees medical, administrative, and development activities. In June 2025, the company appointed Samira Aissani, with expertise in UAE real estate, to lead property acquisitions. Although the exact employee count has not been disclosed, NEWGENIVF’s operations rely on licensed medical professionals, scientific staff, and administrative support personnel.

Fertility Services by Ashton Mullins

Developments and News

On June 12, 2025, NEWGENIVF announced a US$45 million investment in the United Arab Emirates real estate sector, targeting assets near the Wynn Al Marjan Island resort in Ras Al Khaimah and additional properties in Abu Dhabi. Nasdaq issued an Equity Corporate Actions Alert on July 31, 2025, detailing a 1-for-20 reverse stock split and a CUSIP change to regain compliance with the minimum bid price rule. The company filed an amended F-1 registration statement on October 10, 2025, and submitted a Form 424B3 prospectus on October 31, 2025, covering the resale of up to 50 million Class A ordinary shares—20 million issuable to White Lion Capital, LLC, and 30 million arising from warrants and notes.

Financial and Strategic Analysis

As of October 31, 2025, the share price was US$0.7230, down 33.06% on the day, with trading volume at 9,795,544 shares. The 52-week range spans US$0.70 to US$947.00, and market capitalization is approximately US$1.6 million based on 2.15 million shares outstanding. Trailing twelve-month revenue reached US$4.766 million, with a gross margin of 31.51% and a net margin of 12.83%. EBITDA for the same period was US$4.099 million, and the debt-to-equity ratio stood at 37.02%. The prospectus outlines potential gross proceeds of up to US$500 million from share issuances, intended for working capital and general corporate purposes. The US$45 million real estate investment reflects a diversification strategy beyond fertility services.

Market Position and Industry Context

NEWGENIVF operates within the Asia–Pacific assisted reproductive technology market, which is characterized by growing demand, evolving regulations, and technological advancement. The 1-for-20 reverse stock split indicates compliance with Nasdaq listing requirements. Expansion into UAE real estate aims to reduce concentration risk associated with healthcare services by investing in regions with economic stability and infrastructure development. Key risks include managing capital raises, performance of real estate investments, and ongoing adherence to Nasdaq listing standards.

tl;dr

On October 31, 2025, NEWGENIVF’s shares dropped 33.06% to US$0.7230 amid a 1-for-20 reverse stock split. The company filed a prospectus for the resale of up to 50 million shares that could generate US$500 million, and it has allocated US$45 million to investments in UAE real estate in Ras Al Khaimah and Abu Dhabi. Future performance will rely on the success of capital-raising efforts, returns from real estate investments, and continued compliance with listing requirements.